1654-34-8

Usage

Uses

Used in Organic Synthesis:
7-Nitrogramine is used as a reagent in organic synthesis for its chemical reactivity due to the presence of the nitro group. It facilitates a variety of reactions, making it a valuable component in the synthesis of various organic compounds.
Used in Pharmaceutical Research:
7-Nitrogramine is used as a potential pharmacological agent for its anti-inflammatory and antioxidant effects. Its ability to modulate biological processes and exhibit therapeutic properties makes it a promising candidate for further research and development in the pharmaceutical industry.
Used in Catalysis and Chemical Processes:
7-Nitrogramine is used in catalysis and other chemical processes due to its ability to form complex structures with metal ions. This property allows it to act as a catalyst or participate in various chemical reactions, contributing to the advancement of chemical research and technology.

InChI:InChI=1/C11H13N3O2/c1-13(2)7-8-6-12-11-9(8)4-3-5-10(11)14(15)16/h3-6,12H,7H2,1-2H3

Upstream product

• 6960-42-5 7-nitro-1H-indole 
• 51-80-9 bis-(dimethylamino)methane 
• 50-00-0 formaldehyd 
• 124-40-3 dimethyl amine 

Downstream Products

• 1654-32-6 Acetamino-(7-nitro-indolyl-(3)-methyl)-malonsaeure-diethylester 
• 1557-14-8 2-(7-nitro-1H-indol-3-yl)acetic acid 
• 1488-54-6 2-(7-nitro-1H-indol-3-yl)acetonitrile 

Relevant academic research and scientific papers

Rapid Optimization of the Metabolic Stability of a Human Immunodeficiency Virus Type-1 Capsid Inhibitor Using a Multistep Computational Workflow

Poor metabolic stability of the human immunodeficiency virus type-1 (HIV-1) capsid (CA) inhibitor PF-74 is a major concern in its development toward clinical use. To improve on the metabolic stability, we employed a novel multistep computationally driven

SMALL-MOLECULE HIV-1 CAPSID PROTEIN INHIBITORS AND METHODS USING SAME

The present invention provides a method of treating or preventing HIV-1 infection in a subject, comprising the step of administering to the subject one or more of the compounds useful within the invention.

Synthesis and NMR characteristics of N-acetyl-4-nitro, N-acetyl-5-nitro, N-acetyl-6-nitro and N-acetyl-7-nitrotryptophan methyl esters

N-acetyl-4-nitrotryptophan methyl ester (2), N-acetyl-5-nitrotryptophan methyl ester (3), N-acetyl-6-nitrotryptophan methyl ester (4) and N-acetyl-7-nitrotryptophan methyl ester (5) were synthesized through a modified malonic ester reaction of the appropriate nitrogramine analogs followed by methylation with BF3-methanol. Assignments of the 1H and 13C NMR chemical shifts were made using a combination of 1H-1H COSY, 1H-13C HETCOR and 1H-13C selective INEPT experiments. Copyright

TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: wherein variables A1, A2, B, m, n, J, R4, G1, G2, G3 and Y are as described herein, which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

SPIROLACTAM TRICYCLIC CGRP RECEPTOR ANTAGONISTS

Compounds of formula (I): (wherein variables A1, A2, A3, A4, A5, A6, A7, B1, B2, B3, B4, D1, D2, E1, E2, E3, E4, E5, G1, G2, J, K, T, U, V, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

SPIROHYDANTOIN TRICYCLIC CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: (wherein variables A1, A2, A3, A4, A5, A6, A7, B1, B2, B3, B4, D1, D2, E1, E2, E3, E4, E5, G1, G2, R6, T, U, V, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of Formula I: I (where A1, A2, B1, B2, B3, B4, D1, D2, J, K, T, U, V, W, X, Y, Z, R4, R5a, R5b, R5c, m and n are defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.